Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 13, 2013 - Issue 3
Submit an article Journal homepage
609
Views
4
CrossRef citations to date
0
Altmetric
Editorial

Treatment of lung cancer: will financial issues become a criterion of choice?

Alain Vergnenegre Service de Pathologie Respiratoire et d’Allergologie, CHU Dupuytren, Limoges, France and Inserm U707, Paris, France. [email protected]
,
Isabelle Borget Etudes et Recherche en Economie de la Sante, Institut Gustave Roussy, Villejuif, France and Chaire de Droit et Economie Pharmaceutiques, Université Paris-Sud, Orsay, France
&
Christos Chouaid Service de Pneumologie, CHU St Antoine, Paris, France and Inserm U707, Paris, France
Pages 273-275 | Published online: 09 Jan 2014

Citations (4)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Alain Vergnenègre & Christos Chouaïd. (2018) Review of economic analyses of treatment for non-small–cell lung cancer (NSCLC). Expert Review of Pharmacoeconomics & Outcomes Research 18:5, pages 519-528.
Read now

Articles from other publishers (3)

William K. Evans & Claire de Oliveira. (2017) Evaluating Cost-Effectiveness: An Essential Part of New Cancer Drug Approvals. Journal of Thoracic Oncology 12:10, pages 1461-1463.
Crossref
Christos Chouaid, Laura Luciani, Katell LeLay, Pascal Do, Jaafar Bennouna, Maurice Perol, Denis Moro-Sibilot, Alain Vergnenègre & Gérard de Pouvourville. (2017) Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR -Mutated Advanced Non–Small Cell Lung Cancers. Journal of Thoracic Oncology 12:10, pages 1496-1502.
Crossref
Alain Vergnenegre, Bartomeu Massuti, Filippo de Marinis, Enric Carcereny, Enriqueta Felip, Pascal Do, Jose Miguel Sanchez, Luis Paz-Arez, Christos Chouaid & Rafael Rosell. (2016) Economic Analysis of First-Line Treatment with Erlotinib in an EGFR -Mutated Population with Advanced NSCLC. Journal of Thoracic Oncology 11:6, pages 801-807.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.